ALXN1840 could challenge older copper chelators, but gene therapies are coming.
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.